Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege.
AffiliationDepartment of Medicine, Cork University Hospital, National University of Ireland,, Cork, Ireland.
Fas Ligand Protein
Receptors, Tumor Necrosis Factor/biosynthesis
Reverse Transcriptase Polymerase Chain Reaction
MetadataShow full item record
CitationClin Diagn Lab Immunol. 1999 Jul;6(4):457-63.
JournalClinical and diagnostic laboratory immunology
AbstractBreast cancers have been shown to elicit tumor-specific immune responses. As in other types of cancer, the antitumor immune response fails to contain breast tumor growth, and a reduction in both the quantity and cytotoxic effectiveness of tumor-infiltrating lymphocytes (TILs) is associated with a poorer prognosis. Fas ligand (FasL) induces apoptotic death of activated lymphocytes that express its cell surface receptor, FasR (CD95/APO-1). FasL-mediated apoptosis of activated lymphocytes contributes to normal immune downregulation through its roles in tolerance acquisition, immune response termination, and maintenance of immune privilege in the eye, testis, and fetus. In this report, we demonstrate that breast carcinomas express FasL. Using in situ hybridization and immunohistochemistry, we show that breast tumors constitutively express FasL at both the mRNA and protein levels, respectively. FasL expression is prevalent in breast cancer: 100% of breast tumors (17 of 17) were found to express FasL, and expression occurred over more than 50% of the tumor area in all cases. By immunohistochemistry, FasR was found to be coexpressed with FasL throughout large areas of all the breast tumors. This suggests that the tumor cells had acquired intracellular defects in FasL-mediated apoptotic signaling. FasL and FasR expression were independent of tumor type or infiltrative capacity. FasL expressed by tumor cells has previously been shown to kill Fas-sensitive lymphoid cells in vitro and has been associated with apoptosis of TILs in vivo. We conclude that mammary carcinomas express FasL in vivo as a potential inhibitor of the antitumor immune response.
- The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
- Authors: Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F
- Issue date: 1998 Jun 1
- Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
- Authors: Müllauer L, Mosberger I, Grusch M, Rudas M, Chott A
- Issue date: 2000 Jan
- Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer.
- Authors: O'Connell J, Bennett MW, O'Sullivan GC, Roche D, Kelly J, Collins JK, Shanahan F
- Issue date: 1998 Nov
- Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
- Authors: Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, Whiteside TL
- Issue date: 1999 Oct 15
- Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
- Authors: Bodey B, Bodey B Jr, Siegel SE, Kaiser HE
- Issue date: 1999 Jul-Aug